Haptoglobin polymorphism and peripheral arterial occlusive disease

被引:61
作者
Delanghe, J
Langlois, M
Duprez, D
De Buyzere, M
Clement, D
机构
[1] State Univ Ghent Hosp, Dept Clin Chem, B-9000 Ghent, Belgium
[2] Belgian Natl Fund Sci Res, Flanders, Belgium
[3] State Univ Ghent Hosp, Dept Cardiol, B-9000 Ghent, Belgium
关键词
peripheral arterial occlusive disease; atherosclerosis; haptoglobin polymorphism; treadmill testing; angiogenesis;
D O I
10.1016/S0021-9150(99)00079-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haptoglobin (Hp) 2-2 phenotype is a genetic risk factor in coronary atherosclerosis. In this study, haptoglobin phenotypes were determined in 141 patients with peripheral arterial occlusive disease (PAOD) and compared to a reference population (n = 1000). The relative Hpl allele frequency was decreased among PAOD patients (0.294 vs. 0.403 for the reference population, P < 0.01) due to an overrepresentation of the Hp 2-2 phenotype (50%, odds ratio 1.82(95% C.I. 1.28-2.60), P < 0.001). This finding was even more pronounced in non-diabetic and in non-smoking PAOD patients (Hpl allele frequencies: 0.265 and 0.228, respectively). Serum lipids, inflammatory parameters, and blood pressure levels were comparable among the Hp phenotypes, but serum levels of the antioxidant vitamin C were lower in Hp 2-2 patients than in patients with another phenotype (P < 0.05). In PAOD patients with severe atherosclerotic lesions, maximal walking distance of patients carrying a Hp 2-2 phenotype (225-525 m) exceeded that of other Hp phenotypes (50-242 m) (interquartile ranges) (P < 0.05). The findings demonstrate that, despite an increased risk for developing PAOD, the Hp 2-2 phenotype is associated with a longer maximal walking distance which might be attributed to the earlier reported in vitro angiogenic properties of the Hp 2-2 molecule. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 30 条
  • [1] ALLAIN CC, 1974, CLIN CHEM, V20, P470
  • [2] COVARIATION BETWEEN WALKING ABILITY AND CIRCULATORY ALTERATIONS IN PATIENTS WITH INTERMITTENT CLAUDICATION
    ARFVIDSSON, B
    WENNMALM, A
    GELIN, J
    DAHLLOF, AG
    HALLGREN, B
    LUNDHOLM, K
    [J]. EUROPEAN JOURNAL OF VASCULAR SURGERY, 1992, 6 (06): : 642 - 646
  • [3] BEUTLER HO, 1984, METHOD ENZYMAT AN, V6, P376
  • [4] BUCOLO G, 1973, CLIN CHEM, V19, P476
  • [5] EFFECT OF THE HAPTOGLOBIN PHENOTYPE ON THE SIZE OF A MYOCARDIAL INFARCT
    CHAPELLE, JP
    ALBERT, A
    SMEETS, JP
    HEUSGHEM, C
    KULBERTUS, HE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (08) : 457 - 463
  • [6] IDENTIFICATION OF HAPTOGLOBIN AS AN ANGIOGENIC FACTOR IN SERA FROM PATIENTS WITH SYSTEMIC VASCULITIS
    CID, MC
    GRANT, DS
    HOFFMAN, GS
    AUERBACH, R
    FAUCI, AS
    KLEINMAN, HK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (03) : 977 - 985
  • [7] COMPARATIVE DIAGNOSTIC-VALUE OF ANKLE-TO-BRACHIAL INDEX AND TRANSCUTANEOUS OXYGEN-TENSION AT REST AND AFTER EXERCISE IN PATIENTS WITH INTERMITTENT CLAUDICATION
    DEGROOTE, P
    MILLAIRE, A
    DEKLUNDER, G
    MARACHE, P
    DECOULX, E
    DUCLOUX, G
    [J]. ANGIOLOGY, 1995, 46 (02) : 115 - 122
  • [8] Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery
    Delanghe, J
    Cambier, B
    Langlois, M
    DeBuyzere, M
    Neels, H
    DeBacquer, D
    VanCauwelaert, P
    [J]. ATHEROSCLEROSIS, 1997, 132 (02) : 215 - 219
  • [9] DELANGHE J, 1995, J CARDIOVASC RISK, V2, P323
  • [10] HAPTOGLOBIN POLYMORPHISM AND COMPLICATIONS IN ESTABLISHED ESSENTIAL ARTERIAL-HYPERTENSION
    DELANGHE, JR
    DUPREZ, DA
    DEBUYZERE, ML
    BERGEZ, BM
    CALLENS, BY
    LEROUXROELS, GG
    CLEMENT, DL
    [J]. JOURNAL OF HYPERTENSION, 1993, 11 (08) : 861 - 867